StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Investment analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price target on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th.

Minerva Neurosciences Trading Down 1.1 %

Shares of NERV opened at $2.70 on Monday. Minerva Neurosciences has a twelve month low of $2.26 and a twelve month high of $13.49. The company’s fifty day simple moving average is $2.85 and its 200-day simple moving average is $2.80. The company has a market cap of $18.88 million, a P/E ratio of -0.60 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Analysts predict that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.